Importantly, a phase II/III randomized trial of one of these mAbs (relatlimab) in combination with the anti-PD1 mAb nivolumab achieved 48% 12-month progression-free survival in advanced melanoma patients, compared with 36% with nivolumab alone (9). The gene discussed is PDCD1; the disease is melanoma.